16.4 C
United States of America
Sunday, April 12, 2026

The Analyst Verdict: Amgen In The Eyes Of 18 Consultants – Amgen (NASDAQ:AMGN)

Must read



Scores for Amgen (NASDAQ:AMGN) have been offered by 18 analysts previously three months, showcasing a mixture of bullish and bearish views.

Summarizing their current assessments, the desk beneath illustrates the evolving sentiments previously 30 days and compares them to the previous months.

Bullish Considerably Bullish Detached Considerably Bearish Bearish
Complete Scores 3 4 11 0 0
Final 30D 0 0 1 0 0
1M In the past 2 2 5 0 0
2M In the past 1 0 2 0 0
3M In the past 0 2 3 0 0

Analysts have set 12-month value targets for Amgen, revealing a median goal of $350.61, a excessive estimate of $432.00, and a low estimate of $304.00. Witnessing a constructive shift, the present common has risen by 6.93% from the earlier common value goal of $327.88.